Business Wire
21 Jun 2026, 21:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Definium Therapeutics will announce topline results from its Phase 3 Emerge study for DT120 ODT tomorrow. — The event itself is a binary catalyst, but the outcome (success or failure) is unknown, making the announcement of the call neutral until data is released.
+0.00Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Continue reading
6 related stories
Search tags
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
3d ago
